Skip to main content

Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
famotidine
proton pump inhibitors
single-agent H2 receptor antagonists
Description

In this report, we identified new and prevalent users of proton pump inhibitors (PPIs), single-agent H2 receptor antagonists (H2RAs), and famotidine who had a diagnosis of gastroesophageal reflux disease (GERD) in the Rapid Sentinel Distributed Database (SDD). We also estimated the incidence of COVID-19 and COVID-19-related adverse outcomes among these individuals.

The study period includes data from April 1, 2020 to December 15, 2020. We distributed this request to seven Sentinel Data Partners (DPs) on June 3, 2022.

Deliverables (1)
Sentinel Modular Program Report: Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis